Immunic and the University Medical Center Goettingen Sign License Agreement Covering the Combination of DHODH Inhibitors and Nucleoside Analogues to Treat Viral Infections, Including COVID-19PRNewsWire • 09/22/21
Immunic, Inc. to Participate in Investor and Scientific Conferences in SeptemberPRNewsWire • 09/08/21
Immunic, Inc. Reports Second Quarter 2021 Financial Results and Highlights Recent ActivityPRNewsWire • 08/06/21
Immunic Stock Is Trading Lower After Equity Raise Of $45M To Fund Lead Pipeline CandidatesBenzinga • 07/15/21
Immunic, Inc. to Host Virtual R&D Day Today to Provide an Update on the Preclinical and Clinical Development of IMU-935, a Potentially Best-in-Class RORγt Inverse AgonistPRNewsWire • 07/12/21
Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple SclerosisPRNewsWire • 07/01/21
Immunic, Inc. to Participate in Scientific, Industry and Investor Conferences in JulyPRNewsWire • 06/28/21
Immunic, Inc. Reports First Quarter 2021 Financial Results and Highlights Recent ActivityPRNewsWire • 05/06/21
Immunic, Inc. Announces EMPhASIS Interim Analysis of 10 mg Cohort Confirms IMU-838's Dose Response in Relapsing-Remitting Multiple Sclerosis and Supports Phase 3 Dose SelectionPRNewsWire • 04/15/21
Immunic, Inc. to Participate in Scientific, Investor and Industry Conferences in AprilPRNewsWire • 04/13/21
Immunic and 4SC AG Sign Agreement Regarding the Settlement of Royalty Obligations for Immunic's Lead Program, IMU-838PRNewsWire • 03/31/21